Hypoparathyroidism medical therapy: Difference between revisions
Irfan Dotani (talk | contribs) No edit summary |
Irfan Dotani (talk | contribs) No edit summary |
||
| Line 15: | Line 15: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs | [[Category:Needs content]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}} | ||
Revision as of 13:06, 27 July 2016
|
Hypoparathyroidism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypoparathyroidism medical therapy On the Web |
|
American Roentgen Ray Society Images of Hypoparathyroidism medical therapy |
|
Risk calculators and risk factors for Hypoparathyroidism medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Medical Therapy
Severe hypocalcemia, a potentially life-threatening condition, is treated as soon as possible with intravenous calcium (e.g. as calcium gluconate). Generally, a central venous catheter is recommended, as the calcium can irritate peripheral veins and cause phlebitis.
Long-term treatment of hypoparathyroidism is with calcium and Vitamin D3 supplementation (D1 is ineffective in the absence of renal conversion). Teriparatide, a synthetic form of PTH (presently registered for osteoporosis) might become the treatment of choice for PTH supplementation, although further studies are awaited.